RHU GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study

Bone Marrow Transplant. 1991:7 Suppl 2:82.

Authors

N C Gorin¹, B Coiffier, M Hayat, T Philip, J P Vernant, P Hervé, P Colombat, P Boivin, S Slavin, I Eugène-Jolchine

Affiliation

¹ Hôpital Saint-Antoine, France.

PMID: 1878733

No abstract available

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Bone Marrow Transplantation*
Double-Blind Method
Graft Survival / drug effects
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
Hematopoiesis / drug effects*
Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use*
Leukocyte Count / drug effects
Lymphoma, Non-Hodgkin / surgery*
Neutrophils
Recombinant Proteins / pharmacology
Recombinant Proteins / therapeutic use
Transplantation, Autologous

Substances

Immunologic Factors
Recombinant Proteins
Granulocyte-Macrophage Colony-Stimulating Factor